In a Phase 2 clinical trial, we aimed to determine the lutetium-177 [Lu]-PSMA-617 activity and the clinical utility of levels of plasma androgen receptor (AR) gene in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).We determined AR copy number in ...
在2014年,ASCO发布了一份关于mCRPC患者全身治疗的指南,随着新疗法与新的临床管理方式的出现,对于指南的全面更新刻不容缓。 在Journal of Clinical Oncology杂志2022年11月刊上,美国临床肿瘤学会(ASCO)成员发表题为“Systemic Therapy Update on177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer:ASC...
在Journal of Clinical Oncology杂志2022年11月刊上,美国临床肿瘤学会(ASCO)成员发表题为“Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer:ASCO Rapid Recommendation”2的文章,对ASCO指南修订提出建议,介绍在mCRPC应用177Lu-PSMA-617的疗效与优点。 FDA批准该疗法主要...
According to Novartis, the developer of 177Lu-PSMA-617, the PSMAfore study is the first clinical trial of a PSMA-targeted radioligand therapy to demonstrate a clinically meaningful benefit in the pre–taxane-based chemotherapy mCRPC setting. “With the announcement of these positive topline phase ...
The trial randomized patients 2:1 to receive either 177Lu-PSMA-617 plus best SOC (n=551) or best SOC alone (n=280). To be eligible for enrollment, all patients needed to have previously received a GnRH analog or had prior bilateral orchiectomy. In addition, patients needed to have ...
Clinical response was evaluated by questionnaires and radiological response by 68Ga-PSMA-PET/CT. Results Six patients were treated with 177Lu-PSMA: four adenoid cystic carcinomas, one adenocarcinoma NOS and one acinic cell carcinoma. In two patients, radiological response was observed, showing either...
Trial registration: Diagnosis of Adenoid Cystic Carcinoma on 68 Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617 (NCT04801264, Registered 16 March 2021, retrospectively registered). URL of registry: https://clinicaltrials.gov/ct2/show/NCT04801264.Back...
This trial is registered with ClinicalTrials.gov, NCT03392428, and is complete. Findings: 291 men were registered from Feb 6, 2018, to Sept 3, 2019; after study imaging, 200 were eligible and randomly assigned to treatment with [177Lu]Lu-PSMA-617 (n=99) or cabazitaxel (n=101). After...
身份认证 全文购买 相似文献 参考文献 引证文献来源期刊 Clinical nuclear medicine 研究点推荐 Lu-PSMA-617 therapy peptide receptor radionuclide therapy metastatic castration-resistant prostate cancer (mCRPC) 辅助模式 0 引用 文献可以批量引用啦~欢迎点我试用!
TheraP: a randomized phase 2 trial of 177Lu- PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (clinical trial pro- tocol ANZUP 1603). BJU Int. 2019;124(S1):5–13. 8. Derlin, T., et al., (177)Lu-PSMA for extended treatment ...